An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

被引：0

作者：

Krebs, M. ^{[1
,2
]}

Ross, K. ^{[3
]}

Kim, S. ^{[4
]}

De Jonge, M. ^{[5
]}

Barlesi, F. ^{[6
]}

Postel-Vinay, S. ^{[7
]}

Domchek, S. ^{[8
]}

Lee, J. ^{[9
]}

Angell, H. ^{[10
]}

Bui, K. ^{[11
]}

Chang, S. ^{[11
]}

Gresty, C. ^{[10
]}

Herbolsheimer, P. ^{[12
]}

Delord, J. ^{[13
]}

机构：

[1] Univ Manchester, Manchester, Lancs, England

[2] Christie NHS Fdn Trust, Manchester, Lancs, England

[3] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[4] Asan Med Ctr, Seoul, South Korea

[5] Erasmus MC, Canc Inst, Rotterdam, Netherlands

[6] Ctr Essais Precoces Cancerol Marseille, Marseille, France

[7] Gustave Roussy Canc Campus, Villejuif, France

[8] Hosp Univ Penn, Philadelphia, PA 19104 USA

[9] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[10] Astrazeneca, Cambridge, England

[11] Astrazeneca, Waltham, MA USA

[12] Astrazeneca, Gaithersburg, MD USA

[13] Oncopole, Inst Claudius Regaud, Toulouse, France

来源：

关键词：

small-cell lung cancer; olaparib; durvalumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.15-004

引用

页码：S2043 / S2044

页数：2